Skip to main content
SpringerLink
Log in

Solifenacin in Overactive Bladder Syndrome

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Overactive bladder (OAB) syndrome is a prevalent condition, increasingly recognised as a cause of reduced quality of life that places a substantial economic burden on healthcare provision. While antimuscarinic agents are the therapy of choice for OAB, their use is associated with a number of drawbacks, not least of which is the high rate of adverse events, which is intimately linked with poor compliance with treatment.

Solifenacin succinate is a novel antimuscarinic agent approved in Europe and the US for the treatment of men and women with OAB. The recommended starting dose of solifenacin is 5mg once daily and, if needed, the dose may be increased to 10mg once daily. In multiple clinical trials, solifenacin treatment has been associated with statistically significant reductions in all key symptoms of OAB (notably frequency, urgency and incontinence) as well as increases in volume voided. Solifenacin has been shown to be well tolerated, producing few adverse effects, which are usually mild in nature. Furthermore, possibly because of this favourable efficacy and tolerability, solifenacin treatment has been associated with a high rate of patient persistence with therapy, with 81% of 1802 patients who completed 12-week, double-blind trials enrolling in and completing a 40-week open-label extension study. Solifenacin has been shown to display selectivity for bladder versus salivary tissue in vitro, and studies in healthy men have shown that absorption is slow but extensive with an absolute bioavailability of 88%.

Solifenacin is a well tolerated and efficacious agent for the treatment of OAB, significantly reducing symptoms and improving patients’ quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III
Fig. 2
Table IV
Table V
Table VI
Table VII

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Urology 2003; 61(1): 37–49

    Article  PubMed  Google Scholar 

  2. Herbison P, Hay-Smith J, Ellis G, et al. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003; 326(7394): 841–4

    Article  PubMed  CAS  Google Scholar 

  3. Kelleher CJ, Cardozo LD, Khullar V, et al. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104(9): 988–93

    Article  PubMed  CAS  Google Scholar 

  4. MacDiarmid SA. Overactive bladder: improving the efficacy of anticholinergics by dose escalation. Curr Urol Rep 2003; 4(6): 446–51

    Article  PubMed  Google Scholar 

  5. Rovner ES, Wein AJ. Update on overactive bladder: pharmacologic approaches on the horizon. Curr Urol Rep 2003; 4(5): 385–90

    Article  PubMed  Google Scholar 

  6. Ikeda K, Kobayashi S, Suzuki M, et al. M (3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002; 366(2): 97–103

    Article  PubMed  CAS  Google Scholar 

  7. Kobayashi S, Ikeda K, Miyata K. Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilization study in monkey cells. Life Sci 2004; 74(7): 843–53

    Article  PubMed  CAS  Google Scholar 

  8. Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol 2004; 492(2–3): 243–50

    Article  PubMed  CAS  Google Scholar 

  9. Kershen RT, Hsieh M. Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine. Curr Urol Rep 2004; 5(5): 359–67

    Article  PubMed  Google Scholar 

  10. Kuipers M, Tran D, Krauwinkel W, et al. Absolute bioavailability of YM905 in healthy male volunteers: a single-dose, randomized, two-period crossover study [abstract]. International Continence Society 32nd Annual Meeting; 2002 Aug 28–30; Heidelberg

  11. VESIcare® US prescribing information. Deerfield (IL): Astellas Pharma Inc., 2004

  12. Yanagihara T, Kamiyama Y, Iwatsubo T, et al. In vitro metabolism of a new anti-muscarinic agent solifenacin succinate in humans [abstract]. Drug Metab Rev 2003; 35 Suppl. 2: 183

    Google Scholar 

  13. Smulders RA, van Alphen W, Visser J, et al. Multiple dosing with YM905, a novel, bladder-selective antimuscarinic, in healthy men: safety, tolerability, and pharmacokinetics [abstract no. 439]. International Continence Society; 2002 Aug 28–30; Heidelberg

  14. Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol 2004; 44(9): 1023–33

    Article  PubMed  CAS  Google Scholar 

  15. Taekema M, Smulders R, Krauwinkel W. No major differences in pharmacokinetics and tolerability of solifenacin succinate between young and elderly healthy subjects [poster]. 56th Annual Scientific Meeting of the Gerontological Society of America; 2003 Nov 21–25; San Diego (CA)

  16. Smulders R, Smith N, Krauwinkel W, et al. The safety and tolerability of solifenacin succinate in patients with renal disease [poster]. 56th Annual Scientific Meeting of the Gerontological Society of America; 2003 Nov 21–25; San Diego (CA)

  17. Kuipers M, Smulders R, Krauwinkel W. The safety, tolerability and pharmacokinetics of solifenacin succinate in patients with hepatic insufficiency [abstract]. Gerontologist 2003; 143(Special Issue 1): 165

    Google Scholar 

  18. Child C, Turcotte J. Surgery and portal hypertension. In: Child III C, editor. The liver and portal hypertension. Philadelphia (PA): Saunders, 1964: 50–8

    Google Scholar 

  19. Krauwinkel WJJ, Smulders RA, Mulder H, et al. Effect of age on the pharmacokinetics of solifenacin in men and women. Int J Clin Pharmacol Ther 2005; 43(5): 227–38

    PubMed  CAS  Google Scholar 

  20. Michel MC, Minematsu T, Hashimoto T, et al. In vitro studies on the potential of solifenacin for drug-drug-interactions: plasma protein binding and MDR1 transport. Proceedings of the British Pharmacological Society Clinical Pharmacology Section 14–16 December 2004. Br J Clin Pharmacol 2005; 59(5): 647

    Google Scholar 

  21. de Lannoy IA, Silverman M. The MDR1 gene product, p-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun 1992; 189(1): 551–7

    Article  PubMed  Google Scholar 

  22. Fromm MF, Kim RB, Stein CM, et al. Inhibition of p-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99(4): 552–7

    Article  PubMed  CAS  Google Scholar 

  23. Abila B, on behalf of the YM905 study group, Yamanouchi Europe BV. YM905 does not interfere with PK of a combined oral contraceptive [abstract]. Urogynecol J 2002; 13 Suppl. 1: S60

    Article  Google Scholar 

  24. Smith N, van Zijtveld J, Swart PJ. Co-administration of ketoconazole, a potent CYP3A4 inhibitor, does not affect safety or tolerability of YM905 (solifenacin succinate; Vesicare®) [poster 447]. International Continence Society 32nd Annual Meeting; 2002 Aug 28–30; Heidelberg

  25. Uchida T, Krauwinkel WJ, Mulder H et al. Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomised cross-over trial. Br J Clin Pharmacol 2004: 58(1): 4–7

    Article  PubMed  CAS  Google Scholar 

  26. Chapple CR, Arano P, Bosch JL, et al. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004; 93(1): 71–7

    Article  PubMed  CAS  Google Scholar 

  27. Chapple CR, Arano P, Bosch JL, et al. YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase II dose-finding study. International Continence Society 32nd Annual Meeting; 2002 Aug 28–30; Heidelberg

  28. Smith N, Grimes I, Ridge S, et al. YM905 is effective and safe as treatment of overactive bladder in women and men: results from phase II study [poster]. International Continence Society 32nd Annual Meeting; 2002 Aug 28–30; Heidelberg

  29. Uchida T, Tempel D, Ridge S, et al. US PII study results: efficacy and safety of YM905, a bladder selctive treatment for OAB [abstract]. Int Urogynecol J Pelvic Floor Dysfunc 2002; 13 Suppl. 1: S12

    Google Scholar 

  30. Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004; 93(3): 303–10

    Article  PubMed  CAS  Google Scholar 

  31. Cardozo L. Randomized, double-blind placebo-controlled trial of once-daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 2004; 172: 1919–24

    Article  PubMed  CAS  Google Scholar 

  32. Donovan J, Badia X, Corcos J, et al. Symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, et al., editors. Incontinence. 2nd ed. Plymouth: UK Health Publication Ltd, 2002: 267–316

    Google Scholar 

  33. Gittelman M. The efficacy and safety of solifenacin in adults with overactive bladder: a multicenter, placebo-controlled study [abstract no. TP76]. Int J Gynaecol Obstet 2003; 83 Suppl. 3: 94

    Article  Google Scholar 

  34. Gittelman M. Solifenacin succinate 10 mg once daily significantly improves symptoms of overactive bladder [abstract no.62]. American Urology Association Western Congress; 2003 Oct 20–25; Kauai (HI)

  35. Chappie CR, Rechberger T, Al-Shukri S, et al. A double-blind, randomized, placebo- and tolterodine-controlled trial with YM905 (solfenacin succinate) in symptomatic overactive bladder [poster P76]. The American Geriatrics Society meeting; 2003 May 14–18; Baltimore (MD)

  36. Kaufman J, Knapp P, Siami P, et al. YM905 (solifenacin succinate) 10mg increases the proportion of male and female patients with overactive bladder who became continent [poster P168]. The American Geriatrics Society meeting; 2003 May 14–18; Baltimore (MD)

  37. Kelleher C, Cardozo L, Chappie CR, et al. Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 2005; 95(1): 81–5

    Article  PubMed  Google Scholar 

  38. Kelleher CJ, Pleil AM, Reese PR, et al. How much is enough and who says so? BJOG 2004; 111(6): 605–12

    Article  PubMed  Google Scholar 

  39. Haab F, Van Kerrebroeck P, Huang M, et al. Solifenacin associated with high persistence on therapy in long-term overactive bladder extension study [poster]. 3rd International consultation on Incontinence; 2004 Jun 26–28; Monte Carlo

  40. Haab F, Cardozo L, Chappie C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005; 47(3): 376–84. Epub 2005 Jan 5

    Article  PubMed  CAS  Google Scholar 

  41. Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005; 48(3): 464–70

    Article  PubMed  CAS  Google Scholar 

  42. Yu YF, Nichol MB, Yu AP, et al. Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program. Value Health 2005; 8(4): 495–505

    Article  PubMed  Google Scholar 

  43. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003; 62 Suppl. 2: 28–37

    Article  PubMed  Google Scholar 

  44. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87(9): 760–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This review was undertaken with a grant to provide statistical support and research assistance from Yamanouchi Pharmaceutical Co. Ltd (currently Astellas Pharma Inc.), Tokyo, Japan. Dr Payne currently serves as a consultant to Astellas Pharma Inc. and was on an advisory board during development of solifenacin. He did not receive any personal financial support for preparation of this article.

Author information

Authors and Affiliations

  1. Section of Female Urology and NeuroUrology, Stanford University School of Medicine, 300 Pasteur Drive, A260, Stanford, California, 94305-5118, USA

    Christopher K. Payne

Authors
  1. Christopher K. Payne
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Payne, C.K. Solifenacin in Overactive Bladder Syndrome. Drugs 66, 175–190 (2006). https://doi.org/10.2165/00003495-200666020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666020-00004

Keywords

Search

Navigation